Phenylephrine


Description

Phenylephrine is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongati...

Read more

Pharmacology

Indication

Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotensi... Read more

Pharmacodynamic

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agen... Read more

Mechanism of action

In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of... Read more

Absorption

Completely absorbed after oral administration. It has a reduced bioavailability (compared to pseudoe... Read more

Protein binding

95% binding-plasma proteins

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

2.1 to 3.4 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
Varying Reports
Excitability US
Varying Reports
Reflex tachycardia US
Varying Reports
Myocardial Infarction US
Varying Reports
Tachycardia US
Varying Reports
Arrhythmia US
Varying Reports
Subarachnoid hemorrage US
Varying Reports
Restlessness US
Varying Reports
Arrhythmias US
Varying Reports
Eye pain on intillation US
Varying Reports
Temporary blurred vision US
Varying Reports
Temporary photosensitivity US
Varying Reports
Conjunctival sensitization US
Varying Reports
Increased blood pressure US
Varying Reports
Syncope US
Varying Reports

Contraindications

  • Route:
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Dose Form:
    • Injection
  • Regions: US
  • Patient Conditions:
      • Name: Ventricular Tachycardia
      • Drugbank Id: DBCOND0031960
  • Route:
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Dose Form:
    • Injection
  • Regions: US
  • Patient Conditions:
      • Name: Severe Hypertension
      • Drugbank Id: DBCOND0058109
      • Modification Of:
        • Base:
          • Name: Hypertension
          • Drugbank Id: DBCOND0020037
        • Severity:
          • Includes:
            • severe
  • Route:
    • Ophthalmic
  • Regions: US
  • Patient Conditions:
      • Name: Thyrotoxicosis
      • Drugbank Id: DBCOND0021770
  • Route:
    • Ophthalmic
  • Regions: US
  • Patient Conditions:
      • Name: Hypertension
      • Drugbank Id: DBCOND0020037
  • Route:
    • Ophthalmic
  • Hypersensitivity:
    • false
  • Regions: US
  • Route:
    • Ophthalmic
  • Regions: US
  • Age Groups:
    • pediatric
  • Below Age:
    • Amount: 1
    • Unit: year

Food Interactions

  • Take without regard to meals.

Interactions

Type in a drug name to check for interaction with Phenylephrine

The metabolism of (R)-warfarin can be increased when combined with Phenylephrine.
The risk or severity of hypertension can be increased when Phenylephrine is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
The risk or severity of hypertension can be increased when Phenylephrine is combined with 1-benzylimidazole.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 3-isobutyl-1-methyl-7H-xanthine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 3,5-diiodothyropropionic acid.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 3,5-Diiodotyrosine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
The metabolism of Phenylephrine can be decreased when combined with 4-Methoxyamphetamine.
The risk or severity of hypertension can be increased when Phenylephrine is combined with 5-methoxy-N,N-dimethyltryptamine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 6-O-benzylguanine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 7-Deazaguanine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phenylephrine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 7,9-Dimethylguanine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 8-azaguanine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 8-chlorotheophylline.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 9-Deazaguanine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with 9-Methylguanine.
The risk or severity of adverse effects can be increased when Phenylephrine is combined with Abaloparatide.

References

    Information currently not available.

Recent Questions